Format

Send to

Choose Destination
Urol Clin North Am. 2016 Feb;43(1):39-46. doi: 10.1016/j.ucl.2015.08.004.

4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.

Author information

1
Department of Urology, UC San Diego Health, 200 West Arbor Drive #8897, San Diego, CA 92103-8897, USA.
2
Department of Urology, UC San Diego Health, 200 West Arbor Drive #8897, San Diego, CA 92103-8897, USA. Electronic address: jkparsons@ucsd.edu.

Abstract

A preponderance of clinical evidence supports a significant public health benefit for prostate-specific antigen (PSA)-based screening and early detection of prostate cancer in appropriately counseled and selected men. Population-based screening with PSA decreases prostate cancer mortality; however, because of relatively poor specificity, PSA-based screening may also increase the detection of clinically insignificant cancers that would otherwise never require treatment. Use of newer biomarkers that increase the specificity for prostate cancer detection may aid in risk stratification and the appropriate identification of men for prostate biopsy. The authors review the 4-kallikrein panel and 4K probability score.

KEYWORDS:

Biomarker; Detection; Kallikrein panel (4K panel); Kallikrein score (4Kscore); Prostate cancer; Screening

PMID:
26614027
DOI:
10.1016/j.ucl.2015.08.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center